secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028064
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts MyMD IND for Phase 2 study of oral TNF-α inhibitor MYMD-1 in rheumatoid arthritis
--------------------------------------------------------------------------------

- FDA acceptance allows Phase 2 trial in RA; MyMD will discuss timing with CRO IQVIA.
- MYMD-1 is an oral TNF-α inhibitor; existing TNF-α inhibitors require injection or infusion.
- Prior Phase 2 sarcopenia/frailty data showed statistical reduction in TNF-α, IL-6, sTNFR1.
- Company claims MYMD-1 blocks both TNF-α and IL-6, differentiating from current RA treatments.
- Plans to initiate Phase 3 trials in sarcopenia; if approved, first FDA-approved drug for sarcopenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223028064/0001493152-23-028064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223028064/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer